View from Stars and Stripes life guard hut on Miami Beach
Our latest article is part Journal Club entry for August, part look back at some data from AACR and ASCO plus a part look at a relatively new target from an obscure biotech that caught my attention recently.
To do this, we pose three critical questions and attempt to answer them.
The targets and markers chosen for review here may well surprise a few people.
If we want to understand how to help more people respond to cancer immunotherapy then we need o understand the underlying biology and the tumour microenvironment in greater depth than we currently do.
Gradually, we are getting more clarity on a few areas as new data is being published…
To learn more from our latest review of data as well as companies and targets to get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
One of the ongoing challenges with cancer immunotherapy is monitoring response to treatment.
Even if you are one of the minority of people who do respond to cancer immunotherapy, many responders go on to develop acquired resistance or experience immune escape resulting in a loss of response to therapy, which means we need to be able to detect what is happening in the immune system of a cancer patient in order then identify the next treatment option.
Dr Whiteside in the poster hall at #AACR18
Could the proteins and nucleic acids carried by virus sized microvesicles called exosomes – present in their billions in blood plasma – provide insights into biomarkers of response to therapy and what is happening in the tumour?
Some people think they can, while others remain skeptical.
We think it’s cool area of research, worthy of consideration and following as we continue to explore various biopsy and blood/plasma approaches.
One person at the forefront of exosome research is Dr Theresa Whiteside from the University of Pittsburgh, where she’s a Professor of Pathology, Immunology and Otolaryngology.
At the recent 2018 annual meeting at AACR, she kindly spoke about her innovative work over the past year in what is now an exploding field of research…
To learn more from our latest thought leader interview and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
MD Anderson, Houston
Houston, Texas – At the First Annual Symposium on Pancreatic Cancer organized by Ronald DePinho MD and colleagues at the MD Anderson Cancer Center on Monday, one of the presentations that caught my attention was on exosomes.
Raghu Kalluri MD PhD (@KalluriLab) gave an excellent talk on, “Exploiting the Biology of Exosomes for Diagnosis and Therapy of Pancreatic Cancer.”
What were some of the key take homes from his presentation?
He kindly spoke to BSB in Houston and talked about the direction he is going in this rapidly evolving field of research.
Here’s a short snippet from the interview where he talks about one aspect of this approach and how it might be useful (the others are covered in more detail below):
To learn more from our conference commentary and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
At AACR17 one of the fascinating topics that came up in several presentations was exosomes, what they are, and how the information they contain can be used to best effect.
One of the evangelists of exosomes, and their potential in cancer research is Theresa Whiteside, PhD who is a Professor of Pathology, Immunology and Otolaryngology at the University of Pittsburgh.
At the recent 2017 American Association for Cancer Research (AACR) annual meeting, Dr Whiteside gave two fascinating talks in education symposia. Afterwards, she kindly spoke to BSB about her research.
Love them or hate them, exosomes were a hot topic in Washington DC and something you should be aware of, if you aren’t already.
This post continues our volley of expert interviews from AACR17 and is the ninth in the series.
Subscribers can login to read this in-depth interview
Orlando, Florida: It’s time for a review of emerging science and clinical concepts. This post is the final one in our latest series from ASCO-SITC.
Here we take a step back and highlight six key emerging trends and ideas that were either presented in talks and posters, or are sentiments based on conversations with attendees in the poster halls or corridors.
Sometimes those discussions are pretty helpful in giving hints on new dirrections before the actual data eventually comes out.
Subscribers can log-in to read our insights…